Pooja Singhal
Gastroenterology · Oklahoma City, OKNPI 1588825368
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $109,312 of the $139,886 with a category attached, or 78.1%. 33 manufacturers reported payments, led by Sanofi at 32.9% of the total. 2025 is the largest year on record at $44,992, 5.2 times the $8,673 reported in 2019. Among gastroenterology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $445.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$46K
- Johnson & Johnson$33K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$24K
- AbbVie$24K
- Regeneron Healthcare Solutions, Inc.$8K
- Eli Lilly$2K
- plus $3K from 27 others
What the payments were for
- Consulting fees$17,91613%
- Speaking & faculty fees$109,31278%
- Travel & lodging$5,0534%
- Food & beverage$7,5995%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 31 | $46,086 |
| Johnson & Johnson | 56 | $32,899 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 57 | $23,792 |
| AbbVie(2 entities) | 80 | $23,631 |
| Regeneron Healthcare Solutions, Inc. | 13 | $7,953 |
| Eli Lilly | 1 | $2,188 |
| Amgen | 1 | $800 |
| Apollo Endosurgery US Inc | 8 | $690 |
| Janssen Scientific Affairs, LLC | 7 | $429 |
| Lilly USA, LLC | 6 | $228 |
| Phathom Pharmaceuticals, Inc. | 10 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $163 |
| Gilead | 8 | $156 |
| Intercept Pharmaceuticals, Inc. | 1 | $98 |
| Madrigal Pharmaceuticals | 2 | $68 |
| Ipsen Biopharmaceuticals, Inc | 3 | $61 |
| Novo Nordisk | 3 | $58 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Cook Medical LLC | 2 | $41 |
| Ardelyx, Inc. | 2 | $35 |
| Pfizer | 2 | $29 |
| Mauna Kea Technologies, Inc. | 1 | $27 |
| Pharmacosmos Therapeutics Inc. | 1 | $26 |
| Bristol Myers Squibb | 1 | $20 |
| Celltrion USA Inc. | 1 | $20 |
| QOL Medical, LLC | 1 | $19 |
| Vibrant Gastro, Inc. | 1 | $19 |
| Merck | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,886 in reported general payments places this provider in the 95th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 13 | $39,566 |
| LinzessLinaclotide | 23 | $25,321 |
| Mesalamine | 13 | $7,290 |
| Colestipol Hcl | 107 | $5,833 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 23 | $3,868 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 52 | $3,110 |
| Ursodiol | 20 | $2,662 |
| Pantoprazole Sodium | 125 | $2,309 |
| Esomeprazole Magnesium | 25 | $1,044 |
| Dicyclomine Hcl | 32 | $582 |
| Omeprazole | 42 | $444 |
| Sucralfate | 11 | $413 |
| Lactulose | 17 | $399 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 21 | $306 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 20 | $303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $23,792 | $39,56613 claims |
| AbbVieLinzess | $23,631 | $25,32123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Oklahoma City
- George SalemOklahoma City$1.2M
- Tauseef AliOklahoma City$536K
- Hussein BitarOklahoma City$120K
- Trushar PatelOklahoma City$49K
- Matthew McBrideOklahoma City$33K
- Sanjay SikkaOklahoma City$31K
- Tony TranOklahoma City$11K
- Ahmad Al-TaeeOklahoma City$11K
- Sumit WaliaOklahoma City$10K
- Kenneth SeresOklahoma City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.